AbbVie 2012 Annual Report Download - page 151

Footnotes to Outstanding Equity Awards table:
(1) Except as noted, these options are fully vested.
(2) The vesting dates of outstanding unexercisable stock options and unvested restricted stock awards
at December 31, 2012 are as follows:
Option Awards Stock Awards
Number of Number of Number of Number of
Unexercised Number of Number of Number of Shares of Shares of Shares of
Shares Option Option Option Restricted Restricted Restricted
Remaining Shares Shares Shares Number of Stock Stock Stock
from Vesting— Vesting— Vesting— Shares of Vesting— Vesting— Vesting—
Original Date Date Date Restricted Date Date Date
Name Grant Vested 2013 Vested 2014 Vested 2015 Stock Vested 2013 Vested 2014 Vested 2015
R. A. Gonzalez(e) . . . 36,733 18,366—2/18 18,367—2/18 13,333 13,333—2/19
107,300 35,767—2/17 35,766—2/17 35,767—2/17 26,133 (b)
59,400 (c)
L. J. Schumacher(f) . . 19,333 19,333—2/19 32,000 32,000—2/19
38,333 19,166—2/18 19,167—2/18 13,200 (a)
79,800 26,600—2/17 26,600—2/17 26,600—2/17 27,266 (b)
4,011 4,011—1/31 44,200 (c)
30,755 (d)
W. J. Chase ...... 4,467 4,467—2/19 9,000 9,000—2/19
12,666 6,333—2/18 6,333—2/18 3,067 (a)
19,600 6,534—2/17 6,533—2/17 6,533—2/17 9,000 (b)
1,620 1,620—1/31 10,900 (c)
1,591 1,591—3/14 23,066 (d)
3,438 3,438—3/15
C. Alban ........ 11,533 11,533—2/19 21,000 21,000—2/19
30,533 15,266—2/18 15,267—2/18 7,867 (a)
48,100 16,034—2/17 16,033—2/17 16,033—2/17 21,666 (b)
2,482 2,482—1/24 26,700 (c)
18,453 (d)
J. M. Leonard ..... 9,567 9,567—2/19 21,000 21,000—2/19
20,800 10,400—2/18 10,400—2/18 6,533 (a)
33,000 11,000—2/17 11,000—2/17 11,000—2/17 14,800 (b)
18,300 (c)
18,453 (d)
(a) These are the shares of restricted stock that remained outstanding and unvested on December 31, 2012, from
an award made on February 19, 2010. The award has a 5-year term, with no more than one-third of the
original award vesting in any one year upon Abbott achieving a minimum return on equity target, measured
at the end of the relevant year. In 2012, Abbott reached its minimum return on equity target and these shares
vested on February 28, 2013.
(b) These are the shares of restricted stock that remained outstanding and unvested on December 31, 2012, from
an award made on February 18, 2011. The award has a 5-year term, with no more than one-third of the
original award vesting in any one year upon Abbott achieving a minimum return on equity target, measured
at the end of the relevant year. In 2012, Abbott reached its minimum return on equity target and one half of
the unvested shares vested on February 28, 2013.
(c) These are the shares of restricted stock that remained outstanding and unvested on December 31, 2012, from
an award made on February 17, 2012. The award has a 5-year term, with no more than one-third of the
original award vesting in any one year upon Abbott achieving a minimum return on equity target, measured
at the end of the relevant year. In 2012, Abbott reached its minimum return on equity target and one third of
the unvested shares vested on February 28, 2013.
(d) These are the shares of restricted stock that remained outstanding and unvested on December 31, 2012, from
an award made on December 1, 2012. These shares will vest after January 1, 2016 subject to continued
employment with AbbVie through the vesting date and AbbVie achieving a minimum return on equity target
for the period 2013 through 2015.
(e) The table above does not reflect stock options to purchase 320,367 shares of Abbott common stock, which
were transferred in a transaction exempt from Section 16 of the Securities Exchange Act of 1934 under
Rule 16a-12.
(f) The table above does not reflect stock options to purchase 213,752 shares of Abbott common stock, which
were transferred in a transaction exempt from Section 16 of the Securities Exchange Act of 1934 under
Rule 16a-12.
37